The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

British Journal of Haematology

Volumn 129, Issue 5, 2005, Pages 644-652

  Böhm, Martina ^a   Betz, Christoph ^a   Miesbach, Wolfgang ^a   Krause, Manuela ^a   Von Auer, Charis ^a   Geiger, Helmut ^a   Scharrer, Inge ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

ADAMTS 13; Plasma exchange; Thrombotic thrombocytopenic purpura

Indexed keywords

ENZYME INHIBITOR; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE INHIBITOR;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; METHODOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SYMPTOM; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VON WILLEBRAND FACTOR CLEAVING PROTEINASE DEFICIENCY;

ADAM PROTEINS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PROTEASE INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VINCRISTINE; VON WILLEBRAND FACTOR;

EID: 20444500957     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05512.x     Document Type: Article

References (36)

1. Antoine, G., Zimmermann, K., Plaimauer, B., Grillowitzer, M., Studt, J.D., Lämmle, B. & Scheiflinger, F. (2003) ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of Von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. British Journal of Haematology, 120, 821-824.
2. Assink, K., Schiphorst, R., Allford, S., Karpman, D., Etzioni, A., Brichard, B., Van de Kar, N., Monnens, L. & Van den Heuvel, L. (2003) Mutation analysis and clinical implications of Von Willebrand factor-cleaving protease deficiency. Kidney International, 63, 1995-1999.
3. Böhm, M., Vigh, T., Scharrer, I. (2002) Evaluation and clinical application of a new method for measuring activity of Von Willebrand factor-cleaving metalloprotease (ADAMTS13). Annals of Hematology, 81, 430-435.
4. Dong, J.F., Moake, J.L., Nolasco, L., Bernardo, A., Arceneaux, W., Shrimpton, C.N., Schade, A.J., McIntire, L.V., Fujikawa, K. & Lopez, J.A. (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge Von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood, 100, 4033-4039.
5. Ferrara, F., Annunziata, M., Ollio, F., Palmieri, S., Copia, C., Mele, G., Pocal, B. & Schiavone, E.M. (2002) Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Annals of Hematololgy, 81, 7-10.
6. Fontana, S., Kremer Hovinga, J.A., Studt, J.D., Alberio, L., Lämmle, B. & Taleghani, B.M. (2004) Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Seminars in Hematology, 41, 48-59.
7. Fujikawa, K., Suzuki, H., McMullen, B. & Chung, D. (2001) Purification of human Von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 98, 1662-1666.
8. Fujimura, Y. (2003) Is Upshaw-Schulman syndrome congenital thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome? Yes to both. Journal of Thrombosis and Haemostasis, 1, 2457-2458.
9. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrie, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lämmle, B. (1998a) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic Syndrome. New England Journal of Medicine, 339, 1578-1584.
10. Furlan, M., Robles, R., Solenthaler, M. & Lämmle, B. (1998b) Acquired deficiency of Von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 91, 2836-2846.
11. Gerritsen, H.E., Robles, R., Lämmle, B. & Furlan, M. (2001) Partial amino acid sequence of purified Von Willebrand factor-cleaving protease. Blood, 98, 1654-1661.
12. Knöbl, P., Haas, M., Laczika, K., Varadi, K. & Turecek, P.L. (2003) Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. Journal of Thrombosis and Haemostasis, 1, 187-189.
13. Kokame, K., Matsumoto, M., Soejima, K., Yagi, H., Ishizashi, H., Funato, M., Tamai, H., Konno, M., Kamide, K., Kawano, Y., Miyata, T. & Fujimura, Y. (2002) Mutations and common polymorphisms in ADAMTS13 gene responsible for Von Willebrand factor-cleaving protease activity. Proceedings of the National Academy of Sciences of the United States of America, 99, 11902-11907.
14. Kremer Hovinga, J.A., Studt, J.D., Alberio, L. & Lämmle, B. (2004) Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Seminars in Hematololgy, 41, 75-82.
15. Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, J.D., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488-494.
16. Matsumoto, M., Kokame, K., Soejima, K., Miura, M., Hayashi, S., Fujii, Y., Iwai, A., Ito, E., Tsuji, Y., Takeda-Shitaka, M., Iwadate, M., Umeyama, H., Yagi, H., Ishizashi, H., Banno, F., Nakagaki, T., Miyata, T. & Fujimura, Y. (2004) Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood, 103, 1305-1310.
17. Moake, J.L. (2002) Thrombotic thrombocytopenic purpura: the systemic clumping "plague". Annual Review of Medicine, 53, 75-88.
18. Moake, J.L., Rudy, C.K., Troll, J.H., Weinstein, M.J., Colannino, N.M., Azocar, J., Seder, R.H., Hong, S.L. & Deykin, D. (1982) Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. New England Journal of Medicine, 307, 1432-1435.
19. Mori, Y., Wada, H., Gabazza, E.C., Minami, N., Nobori, T., Shiku, H., Yagi, H., Ishizashi, H., Matsumoto, M. & Fujimura, Y. (2002) Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of VWF-cleaving protease activity. Transfusion, 42, 572-580.
20. Moschcowitz, E. (1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proceedings of the New York Pathology Society, 24, 21-24.
21. Nishio, K., Anderson, P.J, Zheng, X.L. & Sadler, J.E. (2004) Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proceedings of the National Academy of Sciences of the United States of America, 101, 10578-10583.
22. Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. & Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 127, 433-439.
23. Pimanda, J.E., Maekawa, A., Wind, T., Paxton, J., Chesterman, C.N. & Hogg, P.J. (2004) Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood, 130, 627-629.
24. Remuzzi, G., Galbusera, M., Noris, M., Canciani, M.T., Daina, E., Bresin, E., Contaretti, S., Caprioli, J., Gamba, S., Ruggenenti, P., Perico, N. & Mannucci, P.M. (2002) Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 100, 778-785.
25. Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. & Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 325, 393-397.
26. Scheiflinger, F., Knöbl, P., Trattner, B., Plaimauer, B., Mohr, G., Dockal, M., Dorner, F. & Rieger, M. (2003) Nonneutralizing IgM and IgG antibodies to Von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood, 102, 3241-3243.
27. Schneppenheim, R., Budde, U., Oyen, F., Angerhaus, D., Aumann, V., Drewke, E., Hasenpflug, W., Häberle, J., Kentouche, K., Kohne, E., Kurnik, K., Mueller-Wiefel, D., Obser, T., Santer, R. & Sykora, K.W. (2003) Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood, 101, 1845-1850.
28. Tsai, H.M. (2000) High titers of inhibitors of Von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. American Journal of Hematology, 65, 251-255.
29. Tsai, H.M. (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Journal of the American Society of Nephrology, 14, 1072-1081.
30. Tsai, H.M. & Lian, E.C. (1998) Antibodies to Von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585-1594.
31. Tsai, H.M., Li, A., Rock, G. (2001) Inhibitors of Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clinical Laboratory, 47, 387-392.
32. Vesely, S.K., George, J.N., Lämmle, B., Studt, J.D., Alberio, L., El-Harake, M.A. & Raskop, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 60-68.
33. Veyradier, A., Obert, B., Houllier, A., Meyer, D. & Girma, J.P. (2001) Specific Von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood, 98, 1765-1772.
34. Veyradier, A., Lavergne, J.M., Ribba, A.S., Obert, B., Loirat, C., Meyer, D. & Girma, J.P. (2004) Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Journal of Thrombosis and Haemostasis, 2, 424-429.
35. Yomtovian, R., Niklinski, W., Silver, B., Sarode, R. & Tsai, H.M. (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. British Journal of Haematology, 124, 787-795.
36. Zheng, X.L., Kaufman, R.M., Goodnough, L.T. & Sadler, J.E. (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 103, 4043-4049.